References
Stein A, Arnold D (2012) Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 13(1):125–137. doi:10.1517/14656566.2012.643870
Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13(16):4832–4839. doi:10.1158/1078-0432.CCR-07-0475
Horimatsu T, Miyamoto S, Morita S, Mashimo Y, Ezoe Y, Muto M, Chiba T (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68(1):263–266. doi:10.1007/s00280-011-1633-9
Gori S, Lunardi G, Inno A, Magarotto R, Duranti S, Messa MG, Mucchino C, Cirillo M (2014) Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer 13(4):260–263. doi:10.1016/j.clcc.2014.09.003
Delord JP, Umlil A, Guimbaud R, Gregoire N, Lafont T, Canal P, Bugat R, Chatelut E (2003) Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 51(2):127–131. doi:10.1007/s00280-002-0550-3
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from the patient described.
Rights and permissions
About this article
Cite this article
Balzer, M.S., Eggers, H., Heuser, M. et al. Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. Ann Hematol 95, 649–650 (2016). https://doi.org/10.1007/s00277-016-2607-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2607-0